Aytu Bioscience (AYTU) Stock: Likely To Benefit From Acrux (ACR) Blues

Aytu Bioscience Inc (OTCMKTS: AYTU) is in a strong position to take advantage of recent news that sent Acrux (ASX: ACR) plummeting. Last week, Eli Lilly (NYSE: LLY) announced that the company ended it’s agreement with Acrux surrounding Axiron, a testosterone replacement therapy for men that is applied to the man’s armpits. This creates a … Read more

Incyte Corporation (INCY) Stock: Takes A Dive As FDA Fails To Approve Treatment

Incyte Corporation (NASDAQ: INCY) is having an incredibly rough day in the market this morning, and for good reason. A treatment that was expected to be approved by the FDA was rejected, causing investor fears and leading to declines in the stock and prompting our partners at Trade Ideas to alert us to the movement. … Read more

Sanofi SA (SNY), Novo Nordisk (NVO) And Eli Lilly (LLY) Stock…Being Sent To The Corn Field

Okay, so unless you are a Twilight Zone enthusiast , you may not catch much of what the title implies, but, trust me, the “corn field” isn’t the most comfortable place to live. And, as of just a short while ago, it appears that three of the biggest makers of diabetes treatments, Sanofi (SNY), Novo … Read more

Eli Lilly Stock (LLY) Implodes On Failed Alzheimer’s Data

Eli Lilly And Co (NYSE: LLY) Eli Lilly stock is getting hammered in pre-market trading on Wednesday, down by over 15% (9:10EST) on news that its drug to treat Alzheimer’s patients, solanezumab, missed the study’s main goal when patients that were taking the drug did not experience a meaningful decline in the loss of cognitive … Read more